Home
Productsindex
Gene
BioActive Proteinsindex
BioActive Biomarker Proteinslists
BioActive Human CCND3 amplification Recombinant Protein,Fc Tag
SGRP00695
BioActive Human CCND3 amplification Recombinant Protein,Fc Tag
Source:Full length Human CCND2 amplification, expressed in HEK293 cells.
SKU:SGRP00695-100UG
Product Name:BioActive Human CCND3 amplification Recombinant Protein,Fc Tag
Product Description:Human CCND3 amplification expressed in HEK293 cells with activity confimed by ELISA.
SKU:SGRP00695-100UG
Product Name:BioActive Human CCND3 amplification Recombinant Protein,Fc Tag
Product Description:Human CCND3 amplification expressed in HEK293 cells with activity confimed by ELISA.
PROPERTIES
Biological Activity:
Fully biologically active
Purity:
> 95% by SDS-PAGE & HPLC
Endotoxin Level:
< 1.0 EU per μg protein as determined by the LAL method
Expression System:
HEK293 Cells
Format:
Recombinant
Species:
Human
Applications:
Sandwich ELISA Functional Studies Mass Spectrometry SDS-PAGE HPLC
Form:
Lyophilized from sterile PBS, pH 7.78
Concentration:
N/A
Stability and Storage:
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution:
Reconstitute with Phosphate Buffered Saline.
Related Categories
BioActive Biomarker Proteins
Background

Gene Accession

P30281

Gene Alias

Protein names Recommended name G1/S-specific cyclin-D3 1 Publication Gene names Name CCND3 1 PublicationImported

Background

Cyclin D3 (CCND3) is a gene that encodes a protein that functions in the regulation of CDK kinases in the cell cycle. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, skin cancer, and stomach cancer. CCND3 is altered in 1.11% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, diffuse large B-cell lymphoma, not otherwise specified, and esophageal adenocarcinoma having the greatest prevalence of alterations. CCND3 Amplification is present in 0.59% of AACR GENIE cases, with breast invasive ductal carcinoma, lung adenocarcinoma, osteosarcoma, esophageal adenocarcinoma, and colon adenocarcinoma having the greatest prevalence.

RECOMMENDED PRODUCTS
BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
ABL1

SGRP00624

BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
ABL1

SGRP00628

BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
AKT1

SGRP00630

BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
AKT1

SGRP00631

BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
ALK

SGRP00637

BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
View Price and Availability
0.118492s